Osgood-Schlatter Market Research Report- Forecast till 2027

Osgood-Schlatter Market Information: By Diagnosis (Physical Examination, Ultrasonography, X-Ray, Combination), Treatment (Non-Steroidal Anti-Inflammatory Drugs, Physical Therapy, Knee Braces and Supports, Surgery), End-User - Forecast till 2027

ID: MRFR/Pharma/3304-HCR | February 2021 | Region: Global | 110 pages

Osgood-Schlatter Market Overview 


Osgood–Schlatter disease (OSD), is the inflammation of area below the knee characterized by a painful bump just below the knee which worsens with activity. OSD typically affects growing adolescents during puberty and is common in those participating in sports and other physical activities. OSD causes a painful lump below the kneecap, resulting in swelling and tenderness affecting the knee. Risk factors include high intensity sports such as running or jumping.


OSD generally resolves with time especially with rest. OSD affects 4% of people at least once in their lifetime and is more common in males between the ages of 10 and 15. The male to female ratio is approximately 5:1.


The symptoms of OSD includes knee pain, swelling, tenderness, increased warmth under the knee and others. In extreme cases OSD may result in fracture.


The market drivers for Osgood-Schlatter market are rise in population, increasing awareness and screening, development of healthcare and orthopaedic centres, rise in sports culture, growth of physiotherapy and advancements in drugs and surgery etc. The market restraints are the complications of treatment such as pain, bleeding, high cost of treatment, competition from alternative treatment and self-correcting nature of the disease etc.


The Osgood-Schlatter market is expected to reach USD 3.7 billion by 2023, and the market is projected to grow at a CAGR of ~ 4.1 % during the forecast period 2017-2023.


Research Methodology
Osgood Schlatter Market


Sources: Mayo Clinic, Healthline Media, MRFR Analysis


Intended Audience



  • Global Osgood-Schlatter manufacturers & suppliers

  • Research and development (R&D) companies

  • Hospitals and clinics

  • Academic institutes and universities


Figure 1 Osgood-Schlatter Market by Hormonal Treatment, 2016 (%) Osgood Schlatter Market-

Segments


The Osgood-Schlatter market has been segmented on the basis of diagnosis, treatment and end user.


Based on the diagnosis, the Osgood-Schlatter market has been segmented as physical examination, ultrasonography, X-ray, combination, and other.


Based on the treatment, the Osgood-Schlatter market has been segmented as non-steroidal anti-inflammatory drugs, physical therapy, knee braces and supports, surgery, and others.


Based on the end user, the Osgood-Schlatter market has been segmented as hospitals & clinics, academic and research, and others.


Regional Analysis


The Americas account for a significant market share owing to high expenditure on the health care. Additionally, the fastest uptake of new healthcare products in the US drives the Osgood-Schlatter market. Furthermore, concentration of the major healthcare companies and hospitals in the developed countries of this region coupled with large insurance penetration is adding fuel to the market growth. Moreover, the US expend high amount on its healthcare, which accounts for 16% of total GDP, which also increases the sale in Osgood-Schlatter market.


Europe is the second largest market in the world due to high income and strong healthcare penetration. The European market growth is led by countries such as Germany and France. The UK is expected to be the fastest growing market over the assessment period. The strong pharmaceutical industry in Germany is a strong driver behind the dominance of this country in Europe.


The large sporting culture and popularity of sports and media influence in the developed regions is expected to drive the future market.


Asia Pacific region is expected to grow rapidly; China and India are likely to lead this market due to fast growing healthcare sector and large unmet needs over the forecast period. South East Asian countries such as China, India, and Malaysia are projected to contribute highly to the market growth. The growing penetration of healthcare insurance in the Asia Pacific region is expected to drive the future Osgood-Schlatter market in the region.


Gulf nations such as Saudi Arabia and the UAE are estimated to drive the Middle East & African market. Other Middle East nations to watch out for are Kuwait, Jordan, Egypt, and Iran. The African region is expected to witness a moderate growth owing to poor economic and political conditions, and poor healthcare development.


Key Players in the Global Osgood-Schlatter Market


Some of the key players profiled in the Osgood-Schlatter market report are DJO Global, Inc., Teva Pharmaceutical Industries Ltd., Breg, Inc., Bayer HealthCare Pharmaceuticals LLC, Ossur HF, Daiichi Sankyo Company, Limited, Pfizer, Inc., Novartis AG, and others.



Report Scope:
Report Attribute/Metric Details
  Market Size

  • 2023: USD 3.7 Billion
  • 2027: Significant Value
  •   CAGR   4.1% (2017-2023)
      Base Year   2019
      Forecast Period   2020-2027
      Historical Data   2018
      Forecast Units   Value (USD Billion)
      Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered   Diagnosis, Treatment and End User
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   DJO Global, Inc., Teva Pharmaceutical Industries Ltd., Breg, Inc., Bayer HealthCare Pharmaceuticals LLC, Ossur HF, Daiichi Sankyo Company, Limited, Pfizer, Inc., Novartis AG, and others
      Key Market Opportunities   New product launches and R&D Amongst major key Players
      Key Market Drivers

  • Rise in population
  • Increasing awareness and screening
  • Development of healthcare and orthopaedic centres
  • Rise in sports culture
  • Growth of physiotherapy
  • Advancements in drugs and surgery


  • Speak to Analyst Ask for Customization

    Table of Content

    1. Report Prologue

    2. Market Introduction

    2.1 Definition

    2.2 Scope of the Study

    2.2.1 Research Objective

    2.2.2 Assumptions

    2.2.3 Limitations

    3. Research Methodology

    3.1 Introduction

    3.2 Primary Research

    3.3 Secondary research

    3.4 Market Size Estimation

    4. Market Dynamics

    4.1 Drivers

    4.2 Restrains

    4.3 Opportunities

    4.4 Challenges

    4.5 Macroeconomic Indicators

    4.6 Technology Trends & Assessment

    5. Market Factor Analysis

    5.1 Porters Five Forces Analysis

    5.2 Value Chain Analysis

    5.3 Investment Feasibility Analysis

    5.4 Pricing Analysis

    6. Global Osgood-Schlatter Market, by Diagnosis

    6.1 Introduction

    6.2 Physical Examination

    6.2.1 Market Estimates & Forecast, 2020-2027

    6.3 Ultrasonography

    6.3.1 Market Estimates & Forecast, 2020-2027

    6.4 X-Ray

    6.4.1 Market Estimates & Forecast, 2020-2027

    6.5 Other

    6.5.1 Market Estimates & Forecast, 2020-2027

    7. Global Osgood-Schlatter Market, by Treatment

    7.1 Introduction

    7.2 Non-Steroidal Anti-Inflammatory Drugs

    7.2.1 Market Estimates & Forecast, 2020-2027

    7.3 Physical Therapy

    7.3.1 Market Estimates & Forecast, 2020-2027

    7.4 Knee Braces and Supports

    7.4.1 Market Estimates & Forecast, 2020-2027

    7.5 Surgery

    7.5.1 Market Estimates & Forecast, 2020-2027

    7.6 Others

    7.6.1 Market Estimates & Forecast, 2020-2027

    8. Global Osgood-Schlatter Market, by End User

    8.1 Introduction

    8.2 Hospitals & Clinics

    8.2.1 Market Estimates & Forecast, 2020-2027

    8.3 Academic and Research Institutes

    8.3.1 Market Estimates & Forecast, 2020-2027

    8.4 Others

    8.4.1 Market Estimates & Forecast, 2020-2027

    9. Global Osgood-Schlatter Market, by Region

    9.1 Introduction

    9.2 Americas

    9.2.1 North America

    9.2.1.1 US

    9.2.1.2 Canada

    9.2.2 South America

    9.3 Europe

    9.3.1 Western Europe

    9.3.1.1 Germany

    9.3.1.2 France

    9.3.1.3 UK

    9.3.1.4 Italy

    9.3.1.5 Spain

    9.3.1.6 Rest of Western Europe

    9.3.2 Eastern Europe

    9.4 Asia Pacific

    9.4.1 Japan

    9.4.2 China

    9.4.3 India

    9.4.4 Australia

    9.4.5 Republic of Korea

    9.4.6 Rest of Asia Pacific

    9.5 The Middle East & Africa

    9.5.1 United Arab Emirates

    9.5.2 Saudi Arabia

    9.5.3 Oman

    9.5.4 Kuwait

    9.5.5 Qatar

    9.5.6 Rest of the Middle East & Africa

    10 Company Landscape

    10.1 Introduction

    10.2 Market Share Analysis

    10.3 Key Development & Strategies

    10.3.1 Key Developments

    11 Company Profiles

    11.1 DJO Global, Inc.

    11.1.1 Company Overview

    11.1.2 Product Overview

    11.1.3 Financials

    11.1.4 SWOT Analysis

    11.2 Teva Pharmaceutical Industries Ltd.

    11.2.1 Company Overview

    11.2.2 Product Overview

    11.2.3 Financial Overview

    11.2.4 Key Developments

    11.2.5 SWOT Analysis

    11.3 Breg, Inc.

    11.3.1 Company Overview

    11.3.2 Product Overview

    11.3.3 Financial Overview

    11.3.4 Key Development

    11.3.5 SWOT Analysis

    11.4 Bayer HealthCare Pharmaceuticals LLC

    11.4.1 Company Overview

    11.4.2 Product/Business Segment Overview

    11.4.3 Financial Overview

    11.4.4 Key Development

    11.4.5 SWOT Analysis

    11.5 PFIZER, INC.

    11.5.1 Company Overview

    11.5.2 Product Overview

    11.5.3 Financial overview

    11.5.4 Key Developments

    11.6 Daiichi Sankyo Company, Limited

    11.6.1 Overview

    11.6.2 Product Overview

    11.6.3 Financials

    11.6.4 Key Developments

    11.6.5 SWOT Analysis

    11.7 Others

    12 MRFR Conclusion

    12.1 Key Findings

    12.1.1 From CEO’s View Point

    12.1.2 Unmet Needs of the Market

    12.2 Key Companies to Watch

    12.3 Prediction of Healthcare Industry

    13 Appendix

    LIST OF TABLES

    Table 1 Osgood-Schlatter Industry Synopsis, 2020-2027

    Table 2 Global Osgood-Schlatter Market Estimates and Forecast, 2020-2027, (USD Million)

    Table 3 Global Osgood-Schlatter Market by Region, 2020-2027, (USD Million)

    Table 4 Global Osgood-Schlatter Market by Diagnosis, 2020-2027, (USD Million)

    Table 5 Global Osgood-Schlatter Market by Treatment, 2020-2027, (USD Million)

    Table 6 Global Osgood-Schlatter Market by End Users, 2020-2027, (USD Million)

    Table 7 North America Osgood-Schlatter Market by Diagnosis, 2020-2027, (USD Million)

    Table 8 North America Osgood-Schlatter Market by Treatment, 2020-2027, (USD Million)

    Table 9 North America Osgood-Schlatter Market by End Users, 2020-2027, (USD Million)

    Table 10 US Osgood-Schlatter Market by Diagnosis, 2020-2027, (USD Million)

    Table 11 US Osgood-Schlatter Market by Treatment, 2020-2027, (USD Million)

    Table 12 US Osgood-Schlatter Market by End Users, 2020-2027, (USD Million)

    Table 13 Canada Osgood-Schlatter Market by Diagnosis, 2020-2027, (USD Million)

    Table 14 Canada Osgood-Schlatter Market by Treatment, 2020-2027, (USD Million)

    Table 15 Canada Osgood-Schlatter Market by End Users, 2020-2027, (USD Million)

    Table 16 South America Osgood-Schlatter Market by Diagnosis, 2020-2027, (USD Million)

    Table 17 South America Osgood-Schlatter Market by Treatment, 2020-2027, (USD Million)

    Table 18 South America Osgood-Schlatter Market by End Users, 2020-2027, (USD Million)

    Table 19 Europe Osgood-Schlatter Market by Diagnosis, 2020-2027, (USD Million)

    Table 20 Europe Osgood-Schlatter Market by Treatment, 2020-2027, (USD Million)

    Table 21 Europe Osgood-Schlatter Market by End Users, 2020-2027, (USD Million)

    Table 22 Western Europe Osgood-Schlatter Market by Diagnosis, 2020-2027, (USD Million)

    Table 23 Western Europe Osgood-Schlatter Market by Treatment, 2020-2027, (USD Million)

    Table 24 Western Europe Osgood-Schlatter Market by End Users, 2020-2027, (USD Million)

    Table 25 Eastern Europe Osgood-Schlatter Market by Diagnosis, 2020-2027, (USD Million)

    Table 26 Eastern Europe Osgood-Schlatter Market by Treatment, 2020-2027, (USD Million)

    Table 27 Eastern Europe Osgood-Schlatter Market by End Users, 2020-2027, (USD Million)

    Table 28 Asia Pacific Osgood-Schlatter Market by Diagnosis, 2020-2027, (USD Million)

    Table 29 Asia Pacific Osgood-Schlatter Market by Treatment, 2020-2027, (USD Million)

    Table 30 Asia Pacific Osgood-Schlatter Market by End Users, 2020-2027, (USD Million)

    Table 31 Middle East & Africa Osgood-Schlatter Market by Diagnosis, 2020-2027, (USD Million)

    Table 32 Middle East & Africa Osgood-Schlatter Market by Treatment, 2020-2027, (USD Million)

    Table 33 Middle East & Africa Osgood-Schlatter Market by End Users, 2020-2027, (USD Million)

    LIST OF FIGURES

    Figure 1 Research Process

    Figure 2 Segmentation for Global Osgood-Schlatter Market

    Figure 3 Segmentation Market Dynamics for Osgood-Schlatter Market

    Figure 4 Global Osgood-Schlatter Market Share, by Diagnosis, 2020

    Figure 5 Global Osgood-Schlatter Market Share, by Treatment, 2020

    Figure 6 Global Osgood-Schlatter Market Share, by End Users, 2020

    Figure 7 Global Osgood-Schlatter Market Share, by Region, 2020

    Figure 8 North America Osgood-Schlatter Market Share, by Country, 2020

    Figure 9 Europe Osgood-Schlatter Market Share, by Country, 2020

    Figure 10 Asia Pacific Osgood-Schlatter Market Share, by Country, 2020

    Figure 11 Middle East & Africa Osgood-Schlatter Market Share, by Country, 2020

    Figure 12 Global Osgood-Schlatter Market: Company Share Analysis, 2020 (%)

    Figure 13 DJO Global, Inc.: Key Financials

    Figure 14 DJO Global, Inc.: Segmental Revenue

    Figure 16 DJO Global, Inc.: Geographical Revenue

    Figure 17 Teva Pharmaceutical Industries Ltd.: Key Financials

    Figure 18 Teva Pharmaceutical Industries Ltd.: Segmental Revenue

    Figure 19 Teva Pharmaceutical Industries Ltd.: Geographical Revenue

    Figure 20 Breg, Inc.: Key Financials

    Figure 21 Breg, Inc.: Segmental Revenue

    Figure 22 Breg, Inc.: Geographical Revenue

    Figure 23 Bayer HealthCare Pharmaceuticals LLC: Key Financials

    Figure 24 Bayer HealthCare Pharmaceuticals LLC: Segmental Revenue

    Figure 25 Bayer HealthCare Pharmaceuticals LLC: Geographical Revenue

    Figure 26 Merck & Co., Inc: Key Financials

    Figure 27 Merck & Co., Inc: Segmental Revenue

    Figure 28 Merck & Co., Inc: Geographical Revenue

    Figure 29 PFIZER, INC.: Key Financials

    Figure 30 PFIZER, INC.: Segmental Revenue

    Figure 31 PFIZER, INC.: Geographical Revenue

    Figure 32 Daiichi Sankyo Company, Limited: Key Financials

    Figure 33 Daiichi Sankyo Company, Limited: Segmental Revenue

    Figure 34 Daiichi Sankyo Company, Limited: Geographical Revenue